Polycomb group molecule PHC3 regulates polycomb complex composition and prognosis of osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Polyhomeotic homolog 3 (PHC3) is implicated as a potential tumor suppressor in osteosarcoma.
• The role of PHC3 in osteosarcoma development and progression requires further elucidation.

Purpose of the Study:

• To investigate PHC3 gene mutations and expression levels in osteosarcoma.
• To analyze the correlation between PHC3 expression and clinical outcomes in osteosarcoma patients.
• To explore the functional role of PHC3 in osteosarcoma cell behavior and its interaction with Polycomb Repressive Complex 1 (PRC1).

Main Methods:

• Mutation screening and quantitative real-time PCR for PHC3 expression analysis in osteosarcoma cell lines and primary samples.
• Correlation analysis of PHC3 expression with patient survival data.
• Functional assays including colony formation assays and Western blotting to assess PHC3's impact on PRC1 components (Bmi1, Ring1b) and cell proliferation.

Main Results:

• Lower PHC3 expression was observed in osteosarcoma tissues compared to normal bone and cell lines.
• Reduced PHC3 expression significantly correlated with poorer overall survival in osteosarcoma patients.
• A specific PHC3 missense mutation (R56P) was identified in a subset of samples and found to abolish its tumor-suppressive activity.
• PHC3 expression suppressed osteosarcoma cell colony formation and reduced Bmi1 and Ring1b protein levels.
• Bmi1 was found to downregulate PHC3 mRNA and promote osteosarcoma cell proliferation.

Conclusions:

• PHC3 functions as a tumor suppressor in osteosarcoma.
• PHC3-mediated tumor suppression is associated with alterations in PRC1 composition.
• PHC3 expression levels are a potential prognostic biomarker for osteosarcoma survival.